Phoenix, AZNCT07104032Now EnrollingIRB Ready

Relapsed/Refractory Primary Central Nervous System Lymphoma Clinical Trial in Phoenix, AZ

Access cutting-edge relapsed/refractory primary central nervous system lymphoma treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.

Sponsored by Ono Pharmaceutical Co., Ltd.

Quick Self-Assessment

See if you qualify for this Phoenix location

Preparing your pre-screening questions…

Expert Care in Phoenix

Access relapsed/refractory primary central nervous system lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related relapsed/refractory primary central nervous system lymphoma treatment provided free

Apply for This Phoenix Location

Check if you qualify for this relapsed/refractory primary central nervous system lymphoma clinical trial in Phoenix, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Phoenix

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Phoenix site if eligible
  4. 4Begin participation

About This Relapsed/Refractory Primary Central Nervous System Lymphoma Study in Phoenix

The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).

Sponsor: Ono Pharmaceutical Co., Ltd.

Who Can Participate

Inclusion Criteria

Pathology report confirming the diagnosis of B-cell PCNSL
Relapsed or refractory B-cell PCNSL with at least 1 prior high-dose methotrexate (HD-MTX) based therapy for PCNSL:
Relapsed disease: Participants who achieved a response (CR, CRu, PR) to the last treatment and subsequently experienced disease progression.
Refractory disease: Participants whose best response to the last treatment was stable disease or PD.
One or more bi-dimensionally measurable brain lesions with a minimum diameter greater than or equal to (≥)1 centimeter (cm) × ≥1 cm in gadolinium-enhanced magnetic resonance imaging (MRI)
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2
Adequate bone marrow, renal, and hepatic function per central lab values
Participants must agree to comply with all defined contraceptive requirements

Exclusion Criteria

Participants with isolated intraocular PCNSL or spinal PCNSL with no brain lesions
Participants with non-B-cell PCNSL
Participants with systemic presence of lymphoma
Refractory to temozolomide with or without rituximab-containing regimens in the last PCNSL treatment
Concomitant systemic corticosteroid exposure within 14 days before starting study drug per Investigator assessment with the exception of the following:
Equivalent of up to 10 milligram per day (mg/day) of prednisone for a disease other than PCNSL
Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day dexamethasone) for participants with lesions of the brain and/or spinal cord
Active malignancy, other than PCNSL requiring systemic therapy
Poorly controlled comorbidity, or history of medical conditions contraindicated per Investigator assessment
Participants who are unable to swallow oral medication
Prior Bruton's tyrosine kinase inhibitor treatment

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Phoenix?

Yes, this clinical trial (NCT07104032) has an active research site in Phoenix, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Relapsed/Refractory Primary Central Nervous System Lymphoma Treatment Options in Phoenix, AZ

If you're searching for relapsed/refractory primary central nervous system lymphoma treatment options in Phoenix, AZ, this clinical trial (NCT07104032) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced relapsed/refractory primary central nervous system lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all relapsed/refractory primary central nervous system lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Phoenix, AZ

See all lymphoma clinical trials recruiting in Phoenix — not just this study.

Browse Lymphoma Trials in Phoenix →

Browse More Trials by Condition

Lymphoma TrialsRheumatoid Arthritis TrialsAntiphospholipid Syndrome TrialsPulmonary Hypertension TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Phoenix?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Phoenix, AZ